Administrative Core

行政核心

• 批准号: 10681256
• 负责人: HAL E. BROXMEYER
• 金额: $ 7.85万
• 依托单位: INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-08-01 至 2026-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10681256
• 关键词: Adopted; Adult; Area; Basic Science; Biochemical; Biology; Biomedical Research; Blood Vessels; Bone Marrow Diseases; Cell Cycle Regulation; Cell Therapy; Cells; Childhood; Clinic; Clinical; Clinical Research; Collaborations; Country; Developmental Biology; Discipline; Disease; Elements; Ensure; Epigenetic Process; Expenditure; Fostering; Funding; Funding Mechanisms; Future; Gene Transfer; Goals; Growth Factor; Health Benefit; Hematology; Hematopoiesis; Hematopoietic; Hematopoietic System; Hematopoietic stem cells; Hereditary Disease; Homing; Human; Immunology; Indiana; Investigation; Medical Genetics; Medicine; Microbiology; Modality; Molecular; Molecular Biology; Molecular Genetics; Mus; National Institute of Diabetes and Digestive and Kidney Diseases; Non-Malignant; Orthopedic Surgery; Pediatrics; Policies; Proliferating; Qualifying; Regulation; Research; Research Personnel; Scientist; Services; Source; Stem cell transplant; Technology; Training Programs; Transplantation; Travel; United States National Institutes of Health; Universities; Work; chemokine; clinical efficacy; cytokine; experience; genetic approach; hematopoietic cell transplantation; hematopoietic tissue; improved; innovative technologies; insight; interest; medical schools; member; migration; progenitor; programs; self-renewal; stem; stem cell biology; stem cells; translational potential

Project Summary The central theme of the Indiana University (IU) Cooperative Center of Excellence in Hematology (CCEH) is the regulation of nonmalignant human and murine hematopoiesis at the level of hematopoietic stem (HSC) and progenitor (HPC) cells, cytokines, chemokines, growth factors, and the microenvironment. This was the focus of the IU-CCEH during the last funding period. We continue to pursue this hefty goal, as we realize that there is still much more that needs to be rigorously defined in these areas. The goals of the investigations of members of this center are to leverage different components of the hematopoietic system to improve and advance clinical utility and efficacy of HSC/HPC-based therapies. Treatment of inherited disorders of bone marrow- derived cells can be achieved by both cellular and genetic approaches that are applicable to many diseases and disorders. However, successful application of these modalities requires a deeper understanding of the cellular, molecular, biochemical HSC and HPC regulation and hematopoietic parameters impacting their efficient use in transplantation such as homing, cell cycle regulation, self-renewal, epigenetics, and the status of the hematopoietic niche. The proposed IU-CCEH brings together the active participation of 25 members who are well funded by the NIH, DoD, or the VA. These investigators are highly interactive with diverse and complementary expertise in hematopoiesis and HSC biology and other disciplines that impact directly or indirectly on multiple components of the hematopoietic system. The IU-CCEH proposes the establishment of 3 biomedical research cores focused on bringing state-of-the-art technologies that advance the work of the members of this center, other similar CCEH centers across the country, and qualified investigators nationwide who do not belong to any NIDDK-funded CCEH. In addition, the IU-CCEH will have an Enrichment Program Core tasked with establishing training programs for young and future scientists interested in nonmalignant hematology research. The specific aims of the IU-CCEH are: 1) Establish, operate, and administer three vital biomedical cores providing essential services to investigators at the IUSM and others outside the IUSM who are involved in the highest quality nonmalignant basic and clinical research in HSC/HPC biology. 2) Establish, operate and administer an Enrichment Program to support, promote and enhance the research of young investigators in the area of nonmalignant HSC regulation and clinical utility of HSC. 3) Actively participate in the implementation of a Partner Pilot and Feasibility funding mechanism organized by all NIDDK-sponsored CCEH centers across the U.S.A. 4) Coordinate fiscal management of the cores of the proposed application. 5) Work closely and cooperate with other CCEH centers nationwide to adopt and implement policies, funding mechanisms, and opportunities via our proposed cores targeting young as well as established investigators to promote and sponsor diverse areas of nonmalignant hematology research at the highest levels.

项目摘要 印第安纳大学（IU）血液学卓越中心（CCEH）的中心主题是 在造血茎（HSC）和 祖细胞（HPC）细胞，细胞因子，趋化因子，生长因子和微环境。这是重点 在最后一个资金期间的IU-CCEH。我们继续实现这一重大目标，因为我们意识到有 在这些领域中，还需要严格定义更多的东西。成员调查的目标 该中心的一个是利用造血系统的不同组成部分来改善和进步 基于HSC/HPC的疗法的临床效用和功效。骨髓遗传疾病的治疗 可以通过适用于许多疾病的细胞和遗传方法来实现衍生细胞 和疾病。但是，这些方式的成功应用需要更深入地了解 细胞，分子，生化HSC和HPC调节以及影响其造血参数 有效地用于移植，例如归巢，细胞周期调节，自我更新，表观遗传学和状态 造血生态位。拟议的IU-CCEH汇集了25名成员的积极参与 由NIH，DOD或VA资助。这些调查人员与多样化和 造血和HSC生物学的互补专业知识以及其他直接影响或 间接在造血系统的多个成分上。 IU-CCEH提议建立3 生物医学研究核心的重点是带来最先进的技术 该中心的成员，全国其他类似的CCEH中心以及全国合格的调查人员 谁不属于任何NIDDK资助的CCEH。此外，IU-CCEH将有一个丰富计划 核心的任务是为对非态度感兴趣的年轻和未来科学家建立培训计划 血液学研究。 IU-CCEH的具体目的是：1）建立，操作和管理三个重要 生物医学核心为IUSM和IUSM以外的其他调查人员提供基本服务的生物医学核心 参与了HSC/HPC生物学中最高质量的非恶性基础和临床研究。 2）建立， 操作和管理一个丰富计划，以支持，促进和增强年轻人的研究 HSC的非恶性HSC调节和临床实用性领域的研究人员。 3）积极参与 所有NIDDK赞助的伙伴飞行员的实施和可行性资金机制 CCEH遍布整个美国。4）协调拟议申请核心的财政管理。 5） 紧密合作并与全国其他CCEH中心合作，以通过和实施政策，资金 通过我们提议的核心以及既定的研究人员的机制和机会 在最高水平上促进和赞助非恶性血液学研究的不同领域。